Is There a European View on Health Economic Evaluations? Results from a Synopsis of Methodological Guidelines Used in the EUnetHTA Partner Countries

Emelie Heintz (), Andreas Gerber-Grote (), Salah Ghabri, Francoise F. Hamers, Valentina Prevolnik Rupel, Renata Slabe-Erker and Thomas Davidson
Additional contact information
Emelie Heintz: Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)
Andreas Gerber-Grote: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
Salah Ghabri: Haute Autorité de Santé (HAS)
Francoise F. Hamers: Haute Autorité de Santé (HAS)
Valentina Prevolnik Rupel: Institute for Economic Research (IER)
Renata Slabe-Erker: Institute for Economic Research (IER)
Thomas Davidson: Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)

PharmacoEconomics, 2016, vol. 34, issue 1, No 7, 59-76

Abstract: Abstract Objectives The objectives of this study were to review current methodological guidelines for economic evaluations of all types of technologies in the 33 countries with organizations involved in the European Network for Health Technology Assessment (EUnetHTA), and to provide a general framework for economic evaluation at a European level. Methods Methodological guidelines for health economic evaluations used by EUnetHTA partners were collected through a survey. Information from each guideline was extracted using a pre-tested extraction template. On the basis of the extracted information, a summary describing the methods used by the EUnetHTA countries was written for each methodological item. General recommendations were formulated for methodological issues where the guidelines of the EUnetHTA partners were in agreement or where the usefulness of economic evaluations may be increased by presenting the results in a specific way. Results At least one contact person from all 33 EUnetHTA countries (100 %) responded to the survey. In total, the review included 51 guidelines, representing 25 countries (eight countries had no methodological guideline for health economic evaluations). On the basis of the results of the extracted information from all 51 guidelines, EUnetHTA issued ten main recommendations for health economic evaluations. Conclusions The presented review of methodological guidelines for health economic evaluations and the consequent recommendations will hopefully improve the comparability, transferability and overall usefulness of economic evaluations performed within EUnetHTA. Nevertheless, there are still methodological issues that need to be investigated further.

Date: 2016
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
http://link.springer.com/10.1007/s40273-015-0328-1 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharme:v:34:y:2016:i:1:d:10.1007_s40273-015-0328-1

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40273

DOI: 10.1007/s40273-015-0328-1

Access Statistics for this article

PharmacoEconomics is currently edited by Timothy Wrightson and Christopher I. Carswell

More articles in PharmacoEconomics from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().